[New Product] Beilu Pharma's Mupirocin Ointment Granted NMPA Approval

Recently, Beilu Pharma received the Drug Registration Certificate for Mupirocin Ointment, approved and issued by the National Medical Products Administration (NMPA).

Developed by GlaxoSmithKline (GSK), Mupirocin Ointment was launched for sale in China in 1993 under the brand name "Bactroban". Mupirocin Ointment is a topical antibiotic indicated for skin infections caused by Gram-positive cocci. Such infections include primary skin infections like impetigo, furuncles, and folliculitis, as well as secondary skin infections such as eczema complicated by infection, and superficial wound infections (where the affected area does not exceed 10cm x 10cm).

Mupirocin Ointment is a Category B product included in the National Reimbursement Drug List (NRDL) and a product of the National Essential Drugs List (NEDL). Data from Menet reveals that Mupirocin Ointment sales across China's three major terminals and six major markets surpassed 1 billion CNY in 2024. In the first half of 2025, sales recorded a year-on-year growth of 4.41%.

Mupirocin Ointment was approved as a Class 4 chemical drug, deemed to have passed the consistency evaluation for generic drug quality and efficacy. This milestone will further enrich the company’s portfolio of dermatological medications and enhance the market competitiveness of the products. The company will actively carry out preparations for the launch of the new product and strive to bring it to market as soon as possible.